# Matt Kraning, Angel Investor

Investor in San Francisco, California

## About Matt Kraning, Angel Investor

Matt Kraning is a technology entrepreneur, investor, and cybersecurity leader recognized for shaping the attack surface management sector. He co-founded Expanse in 2012, pioneering visibility and defense solutions for enterprise networks before its $1.25 billion acquisition by Palo Alto Networks, where he later served as CTO of Cortex—overseeing AI-driven cybersecurity innovation and guiding a business unit exceeding $1 billion in annual sales.

Kraning began his career as a consultant for DARPA, contributing to advanced defense research in distributed computing and large-scale data systems. He currently serves as a board director at Wispr Flow, a next-generation AI and hardware company redefining human–computer interaction.

As an active angel investor, Kraning has supported over twenty early-stage ventures across AI, security, and enterprise infrastructure. His portfolio includes Summation, Wispr Flow, and Peregrine Technologies, reflecting his ongoing focus on transformative deep-tech and applied AI companies.

## People

- **Matt Kraning**, Angel Investor

## Key Facts

- **Location:** San Francisco, California
- **Investor Type:** Angel Investor

## Investment Industries

- Artificial Intelligence (AI)
- Technology/Web/App
- Other

## How to Contact

Direct messaging, this investor's website, and their Facebook profile are available with a paid Ask For Funding plan.

- [See plans and pricing](https://askforfunding.com/pricing)
- Already on a paid plan? [Log in](https://askforfunding.com/users/sign_in)

## More on Ask For Funding

- Full profile: https://askforfunding.com/investor/matt-kraning-angel-investor
- More investors: [AI Investors in California](https://askforfunding.com/site/angel-investors/california/ai)
- Find more investors: https://askforfunding.com/search/investors

Ask For Funding (AskForFunding.com) connects entrepreneurs with angel investors, private investors and venture capital firms in the United States, Canada and Australia.
